Cencora (COR) has set August 5, 2026 for the release of its fiscal third quarter results, with a conference call scheduled before the market opens. This puts the upcoming earnings firmly on investors’ calendars.

Cencora’s recent momentum has picked up, with a 1 day share price return of 2.80% and a 30 day share price return of 9.69%. The 1 year total shareholder return of 0.85% compares with a 3 year total shareholder return of 59.41% and a 5 year total shareholder return of 171.16%. This points to a stock where long term holders have seen far larger gains than those focused only on the past year.

If Cencora’s setup has you thinking more broadly about healthcare, this could be a good moment to scan for other potential opportunities with the 40 healthcare AI stocks

With Cencora trading at $296.51 and flagged as having an intrinsic discount of 40.96% alongside a value score of 5, the key question is whether investors are seeing a genuine valuation gap or if the market is already pricing in future growth.

Most Popular Narrative: 15.4% Undervalued

At a last close of $296.51 versus a most followed fair value of $350.58, Cencora is framed as undervalued in this narrative, with the discount rate set at 7.11% to bring future cash flows back to today.

Cencora's ongoing investment in digital infrastructure and advanced analytics positions the company to capitalize on the accelerating digitization of healthcare and regulatory requirements like the Drug Supply Chain Security Act, improving supply chain efficiency and transparency, which should drive higher net margins and operating income over time.

Want to see how this Cencora story translates into numbers? The narrative focuses on mid single digit revenue growth, firming margins, and a richer future earnings multiple. Curious which assumptions really contribute to that $350.58 fair value and 15.4% discount label?

Result: Fair Value of $350.58 (UNDERVALUED)

However, the Cencora story could be knocked off course if regulatory scrutiny on drug pricing tightens further, or if competition in specialty distribution pressures margins more than expected.

Next Steps

With Cencora attracting both optimism and concern in this narrative, it makes sense to quickly review the full mix of potential outcomes yourself. To weigh those trade offs clearly, start with the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Cencora?

If Cencora has sharpened your focus, do not stop here. Broaden your watchlist with a few targeted stock ideas that match different investing priorities.

• Target potential income stability by reviewing companies in the 7 dividend fortresses that might suit a yield focused portfolio.
• Zero in on financial resilience by checking companies featured in the solid balance sheet and fundamentals stocks screener (47 results) for stronger balance sheets and fundamentals.
• Hunt for lesser known opportunities by scanning the screener containing 18 high quality undiscovered gems before others catch on to them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.